ActiveMatrix ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05297513 (ClinicalTrials.gov) | July 2022 | 17/3/2022 | Efficacy of ActiveMatrix on Spinal SSI Rate | Efficacy of ActiveMatrix on Spinal Surgical Site Infection (SSI) Reduction: A Single-blinded Randomized Controlled Trial | Spinal Stenosis Lumbar;Surgical Site Infection;Back Pain Lower Back Chronic | Drug: ActiveMatrix | Baylor College of Medicine | Skye Biologics | Not yet recruiting | 18 Years | 100 Years | All | 275 | Phase 4 | NULL |